Mucinous cystadenocarcinoma

MONDO:0005858

An invasive adenocarcinoma characterized by cystic changes and the presence of malignant glandular cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.

Also known as: Pseudomucinous adenocarcinoma, Pseudomucinous cystadenocarcinoma, mucinous cystadenocarcinoma, mucinous cystadenocarcinoma (morphologic abnormality), mucinous cystadenocarcinoma NOS (morphologic abnormality)

2744 clinical trials for this condition and its sub-types, 1 tagged with Mucinous cystadenocarcinoma itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Mucinous adenocarcinoma (57) ↑ Cystadenocarcinoma (6)

Sub-types of Mucinous cystadenocarcinoma

Ovarian mucinous cystadenocarcinoma 4 trials
Appendix mucinous cystadenocarcinoma 0 trials
Breast mucinous cystadenocarcinoma 0 trials
Pancreatic mucinous cystadenocarcinoma 0 trials
2 sub-types
- Pancreatic mucinous-cystic neoplasm with an associated invasive carcinoma 0 trials
- Pancreatic non-invasive mucinous cystadenocarcinoma 0 trials

Including sub-types (2744) Tagged with Mucinous cystadenocarcinoma (1)

Not yet finished but already full! 1

Immunotherapy duo takes on rare tumors

Disease control Ongoing

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

Mucinous cystadenocarcinoma

Where it sits in the disease tree

Immunotherapy duo takes on rare tumors